SCHEMBL22746738

SCHEMBL22746738

c1ccc(-c2cccc(-n3c4ccc(-c5nc6ccccc6o5)cc4c4cc(-c5nc6ccccc6o5)ccc43)c2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 8/20 0.55
▸ SMN1; SMN2 Q16637 7/20 0.55
▸ ALDH1A1 P00352 7/20 0.55
▸ HSD17B10 Q99714 6/20 0.55
▸ HPGD P15428 6/20 0.55
▸ TP53 P04637 5/20 0.55
▸ KMT2A Q03164 4/20 0.55
▸ MEN1 O00255 3/20 0.55
▸ PKM P14618 1/20 0.55
▸ HPSE Q9Y251 3/20 0.48
▸ NPC1 O15118 8/20 0.47
▸ RAB9A P51151 6/20 0.47
▸ HCRTR1 O43613 2/20 0.47
▸ MAPT P10636 2/20 0.47
▸ USP2 O75604 1/20 0.47
▸ TSHR P16473 1/20 0.47
▸ MAPK1 P28482 1/20 0.47
▸ CASP3 P42574 1/20 0.47
▸ NPSR1 Q6W5P4 1/20 0.47
▸ SENP8 Q96LD8 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22747050 0.96 KDM4E (0.58) KDM4ESMN1; SMN2ALDH1A1HSD17B10HPGD
SCHEMBL10065303 0.95 KDM4E (0.52) KDM4ESMN1; SMN2ALDH1A1HSD17B10HPGD
SCHEMBL10065302 0.95 SMN1; SMN2 (0.51) KDM4ESMN1; SMN2ALDH1A1HSD17B10HPGD
SCHEMBL10065301 0.95 SMN1; SMN2 (0.51) KDM4ESMN1; SMN2ALDH1A1HSD17B10HPGD
SCHEMBL10065406 0.94 HSD17B10 (0.49) KDM4ESMN1; SMN2ALDH1A1HSD17B10HPGD
SCHEMBL22747039 0.94 KDM4E (0.52) KDM4ESMN1; SMN2ALDH1A1HSD17B10HPGD
SCHEMBL23108422 0.94 KDM4E (0.54) KDM4ESMN1; SMN2ALDH1A1HSD17B10HPGD
SCHEMBL22746737 0.93 TP53 (0.54) KDM4ESMN1; SMN2ALDH1A1HSD17B10HPGD
SCHEMBL23108466 0.93 KDM4E (0.51) KDM4ESMN1; SMN2ALDH1A1HSD17B10HPGD
SCHEMBL22747043 0.93 KDM4E (0.51) KDM4ESMN1; SMN2ALDH1A1HSD17B10HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200377492-A1 ORGANIC ELECTROLUMINESCENT COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE INCLUDING THE SAME P&H TECH CO., LTD 2020-12-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200377492-A1 ORGANIC ELECTROLUMINESCENT COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE INCLUDING THE SAME OCIAD1, OCIAD2, POU2F1 KDM4E 1834/4885SMN1; SMN2 4572/4885ALDH1A1 582/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback